EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in research on pharmacological mechanisms of anatabine: from nicotinic modulation to multitarget therapeutic potential

Xiaonan Li, Xiaomin Liu, Huaquan Sheng, Jianfeng Guo, Leihao Zhang, Ting Fei, Yihan Gao

Experimental Biology and Medicine · 29.06.2026 · 251

DOI: 10.3389/ebm.2026.11069 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Experimental Biology and Medicine, online erschienen am 29.06.2026. Verfasst von Xiaonan Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Basic Research Department, Shanghai New Tobacco Product Research Institute Co., Ltd. (SNTPRI), Shanghai, China. Hauptthemen laut MEDLINE: Alkaloids, Pyridines, Receptors, Nicotinic. Die Arbeit nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anatabine, a characteristic minor alkaloid derived from tobacco byproducts, exhibits unique structural analogy to nicotine but possesses a superior safety profile and lower addictive liability, rendering it a promising natural multi-target therapeutic candidate. Accumulating preclinical evidence has demonstrated that anatabine exerts neuroprotective, anti-inflammatory, and antioxidant effects mainly through modulating α7/α4β2 nicotinic acetylcholine receptors, suppressing NF-κB/STAT3 inflammatory signaling, and activating the Nrf2-mediated antioxidant pathway. It effectively ameliorates typical pathological alterations, including β-amyloid deposition, tau hyperphosphorylation, and microglial overactivation, thereby improving cognitive and behavioral deficits in neurodegenerative disease models. Additionally, anatabine displays broad pharmacological potentials in chronic inflammation, autoimmune thyroiditis, asthma, and hypertension. Differing from previous reviews that merely focused on single receptor regulation, the present work systematically summarizes the multi-target pharmacological characteristics of anatabine, comprehensively collates its preclinical efficacy across multiple disease categories, and highlights its advantages over nicotine in safety and addiction risk. Furthermore, we analyze the current limitations, druggability optimization challenges, and clinical translation prospects, and propose sustainable strategies for high-value utilization of tobacco byproducts. This review provides an updated and systematic theoretical basis for further mechanism exploration and therapeutic development of anatabine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlkaloidsPyridinesReceptors, NicotinicHumansAnimalsNeuroprotective AgentsAntioxidantsAnti-Inflammatory Agents

Stichwörter der Autor:innen

Alzheimer’s diseaseNF-κBalkaloidsanatabineanti-inflammatoryneurological disorderspharmacological mechanisms

Substanzen

anatabineAlkaloidsPyridinesReceptors, NicotinicNeuroprotective AgentsAntioxidantsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Basic Research Department, Shanghai New Tobacco Product Research Institute Co., Ltd. (SNTPRI), Shanghai, China.

Zitieren

APA

Li, X., Liu, X., Sheng, H., Guo, J., Zhang, L., Fei, T., & Gao, Y. (2026). Advances in research on pharmacological mechanisms of anatabine: from nicotinic modulation to multitarget therapeutic potential. Experimental Biology and Medicine, 251. https://doi.org/10.3389/ebm.2026.11069

Vancouver

Li X, Liu X, Sheng H, Guo J, Zhang L, Fei T, et al. Advances in research on pharmacological mechanisms of anatabine: from nicotinic modulation to multitarget therapeutic potential. Experimental Biology and Medicine. 2026;251. doi:10.3389/ebm.2026.11069

BibTeX
@article{Li2026,
  author = {Li, Xiaonan and Liu, Xiaomin and Sheng, Huaquan and Guo, Jianfeng and Zhang, Leihao and Fei, Ting and Gao, Yihan},
  title = {Advances in research on pharmacological mechanisms of anatabine: from nicotinic modulation to multitarget therapeutic potential},
  journal = {Experimental Biology and Medicine},
  year = {2026},
  volume = {251},
  doi = {10.3389/ebm.2026.11069}
}
Kostenlos starten →